



Market Announcement

6 March 2025

Anatara Lifesciences Ltd (ASX: ANR) – Trading Halt

Description

The securities of Anatara Lifesciences Ltd ('ANR') will be placed in trading halt at the request of ANR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 10 March 2025 or when the announcement is released to the market.

Issued by

ASX Compliance

6 March 2025

ASX Compliance Pty Ltd (ASX)
20 Bridge St
Sydney NSW 3000

By email: tradinghaltssydney@asx.com.au

Dear Sir or Madam,

Trading Halt Request

In accordance with ASX Listing Rule 17.1, Anatara Lifesciences Limited (ASX:ANR) (**Company**) hereby requests a trading halt over the Company's securities, effective immediately, pending an announcement regarding an update on the Phase II GaRP-IBS (Irritable Bowel Syndrome) Trial Stage 2.

The Company requests that the trading halt lasts from the receipt of this request until the earlier of release of the announcement or the commencement of trading on 10 March 2025.

The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

If you have any further queries or require further information, please do not hesitate to contact me.

Yours sincerely

Jonathan W. Lindh
Company Secretary
Anatara Lifesciences Limited

Anatara Lifesciences Limited
Registered Office
C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com

